A Phase 1b Study of MEDI4920 in Participants With Adult-onset Rheumatoid Arthritis

Completed · Phase 1 · Has a placebo group

Conditions studied: Adult Onset Rheumatoid Arthritis

In brief

The purpose of this study is to determine whether VIB4920 (formerly MEDI4920) is safe and well tolerated in participants with adult-onset rheumatoid arthritis (RA).

Key facts

Study ID

NCT02780388

Run by

Amgen

People needed

57

Starts

2016-05-12

Expected to finish

2018-08-09

Last updated by the study team

2024-12-27

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• adult-onset rheumatoid arthritis
• swollen and tender joints

You may not qualify if…

• venous thromboembolism or arterial thrombosis
• pregnant or breastfeeding
• positive hepatitis B, hepatitis C, and human immunodeficiency virus infection
• active or untreated latent tuberculosis

Where it is running

• Research Site — Anniston, Alabama, United States
• Research Site — DeBary, Florida, United States
• Research Site — Jacksonville, Florida, United States
• Research Site — Miami Lakes, Florida, United States
• Research Site — South Miami, Florida, United States
• Research Site — Cincinnati, Ohio, United States
• Research Site — Duncansville, Pennsylvania, United States
• Research Site — Mesquite, Texas, United States
• Research Site — Bialystok, Poland
• Research Site — Bydgoszcz, Poland
• Research Site — Poznan, Poland
• Research Site — Warsaw, Poland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.